Solid Biosciences Inc. SLDB Accretion (Amortization) of Discounts and Premiums, Investments
Accretion (Amortization) of Discounts and Premiums, Investments at other companies
Other financials
Where this comes from
Reported directly by Solid Biosciences Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments.
The official record: Solid Biosciences Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Solid Biosciences Inc.'s accretion (amortization) of discounts and premiums, investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Solid Biosciences Inc.'s accretion (amortization) of discounts and premiums, investments?
- Solid Biosciences Inc. (SLDB) reported accretion (amortization) of discounts and premiums, investments of $619K in Q1 2026.
- How has Solid Biosciences Inc.'s accretion (amortization) of discounts and premiums, investments changed year-over-year?
- Solid Biosciences Inc.'s accretion (amortization) of discounts and premiums, investments increased by 98.4% year-over-year, from $312K to $619K.
- What is the long-term trend for Solid Biosciences Inc.'s accretion (amortization) of discounts and premiums, investments?
- Over 2 years (2023 to 2025), Solid Biosciences Inc.'s accretion (amortization) of discounts and premiums, investments has grown at a -11.8% compound annual growth rate (CAGR), from $2.41M to $1.87M.
- What does accretion (amortization) of discounts and premiums, investments mean?
- This represents the non-cash adjustment to reconcile net income for the periodic amortization of premiums or accretion of discounts on investment securities. It reflects the gradual adjustment of the carrying value of debt securities toward their par value over time. Investors use this to isolate the impact of investment valuation changes from actual cash flows generated by operations.